Risk of adverse events with fibrates.
作者信息
Alsheikh-Ali Alawi A, Kuvin Jeffrey T, Karas Richard H
机构信息
Molecular Cardiology Research Institute, Department of Medicine, Division of Cardiology, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
出版信息
Am J Cardiol. 2004 Oct 1;94(7):935-8. doi: 10.1016/j.amjcard.2004.06.033.
Abstract
An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis. This difference was especially noticeable in patients taking the combination of gemfibrozil and a statin, particularly cerivastatin.
摘要
Zotero 插件